Crossmark

Immune oncology, immune responsiveness and the theory of everything

Crossref DOI link: https://doi.org/10.1186/s40425-018-0355-5

Published Online: 2018-06-05

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Turan, Tolga

Kannan, Deepti

Patel, Maulik

Matthew Barnes, J.

Tanlimco, Sonia G.

Lu, Rongze

Halliwill, Kyle

Kongpachith, Sarah

Kline, Douglas E.

Hendrickx, Wouter

Cesano, Alessandra

Butterfield, Lisa H.

Kaufman, Howard L.

Hudson, Thomas J.

Bedognetti, Davide

Marincola, Francesco

Samayoa, Josue https://orcid.org/0000-0003-3609-8954
License Information

Text and Data Mining valid from 2018-06-05
More Information

Article History

Received: 22 November 2017

Accepted: 11 May 2018

First Online: 5 June 2018

Ethics approval and consent to participate

: The results shown here are based upon data generated by the TCGA Research Network:. All of the data used for this study was obtained as described in Hendrickx et al., 2017.

: Dr. Howard L. Kaufman has served on advisory boards for Amgen, Celldex, Compass Therapeutics, EMD Serono, Merck, Prometheus and Turnstone Biologics. He serves on a speaker’s bureau for Merck but all honoraria are returned to Rutgers University. Alessandra Cesano is Chief Medical Officer at Nanostring whose platform is mentioned in the text.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.